AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24949605
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PMC (PMC4/0)
Trial: 24949605
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PEG (PEG4/0)
Trial: 24949605
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose PMC (PMC2/2)
Trial: 24949605
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose PEG (PEG3/1)
Trial: 24949605
Drug: Split PMC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split PMC dose
Trial: 22337905
Drug: Dexamethasone (DEX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (DEX; 1 mg)
Trial: 20167180
Drug: Insulin detemir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin detemir, dosed once daily
Trial: 20167180
Drug: Insulin glargine,
RxNorm normalized name: insulin glargine, human recombin. analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine, dosed once daily
Trial: 12578294
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with 1 IU ml(‐1) of heparin (n = 35)
Trial: 12578294
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin (n = 31)
Trial: 7188378
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg zopiclone
Trial: 7188378
Drug: 10.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg zopiclone
Trial: 26062880
Drug: Dual treatment
RxNorm normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual treatment
Trial: 21710405
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication (various neuroleptic medications)
Trial: 19526753
Drug: Compound Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Astragalus Recipe (CAR)
Trial: 12117080
Drug: Budesonide administered
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide administered by Turbuhaler (DPI)
Trial: 12117080
Drug: Budesonide therapy
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide therapy
Trial: 12117080
Drug: Pulmicort Respules
RxNorm normalized name: Pulmicort Respules
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort Respules (nebulized formulation)
Trial: 19565392
Drug: Lee Silverman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lee Silverman Voice Treatment (LSVT)
Trial: 8960734
Drug: Placebo (respiration)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (respiration) treatment
Trial: 6122057
Drug: Oral amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amphotericin B and nystatin
Trial: 25732163
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg per day until progression
Trial: 22865498
Drug: 0.85 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85 g/day eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) (low dose)
Trial: 22865498
Drug: 3.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g/day EPA + DHA (high dose)
Trial: 17472824
Drug: Trial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial preparation of TMP/SMX 40/200 mg per 5-ml, oral suspension
Trial: 17472824
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation of TMP/SMX 40/200 mg per 5-ml, oral suspension
Trial: 9590144
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) given as 200 microg/m2/d SC starting one day after HD C/T until neutrophil recovery
Trial: 9590144
Drug: High-dose cytarabine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine-containing chemotherapy (HD C/T) without G-CSF
Trial: 2713211
Drug: Bromocriptine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (1.25 mg)
Trial: 2713211
Drug: Lisuride (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (0.1 mg)
Trial: 2713211
Drug: Terguride (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terguride (0.25 mg)
Trial: 12470401
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose insulin with glucose, potassium and amino acids
Trial: 7543114
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of GH (3.15 +/- 0.27 IU daily)
Trial: 7543114
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections of GH (3.15 +/- 0.27 IU daily)
Trial: 330937
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg methylproscillaridin (MP)
Trial: 25005784
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium citrate 150 mg twice daily
Trial: 8584148
Drug: Ketamine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (6 micrograms/kg/min after a bolus dose of 60 micrograms/kg)
Trial: 8584148
Drug: Alfentanil (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (0.6 microgram/kg/min after a bolus dose of 7 micrograms/kg)
Trial: 8218755
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cisapride q.d.s.
Trial: 31735500
Drug: ChAdOx1 85A
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 85A alone (low dose Starter Group, n=6)
Trial: 30980618
Drug: cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream containing herbal mixture
Trial: 30980618
Drug: arbutin cream
DrugBank: Arbutin (DB11217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: arbutin cream
Trial: 27853882
Drug: hANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hANP infusion
Trial: 20030859
Drug: Western and
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western and Chinese medicine together (Group B)
Trial: 20030859
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine only (Group A)
Trial: 17846293
Drug: i.v. low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. low dose nesiritide (0.005 microg/Kg/min for 24 hours)
Trial: 15118189
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin E, 500 mg/d; vitamin C, 1 g/d; beta-carotene, 30 mg/d)
Trial: 11697418
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg retinol equivalent (RE) with childhood immunization
Trial: 11697418
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg retinol equivalent (RE) with childhood immunization
Trial: 22882543
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 µg twice a day, n = 30)
Trial: 22882543
Drug: Fluticasone (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (125 µg twice a day, n = 10)
Trial: 20729742
Drug: pegylated interferon‐α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated interferon‐α‐2a (180 μg/week) and ribavirin (1000‐1200 mg/day) for 48 weeks
Trial: 12540501
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of 4‐HPR/day for 5 years
Trial: 10876750
Drug: Continuous irrigation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous irrigation with 40 micrograms/ml epirubicin solution for 20 hours after surgery
Trial: 10876750
Drug: Continuous irrigation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous irrigation with 40 micrograms/ml epirubicin solution for 20 hours after surgery (for solitary tumors)
Trial: 2942293
Drug: Kangbao Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangbao Solution
Trial: 22127619
Drug: Standard prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prescription instructions (usual care)
Trial: 18194120
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (steroid-free regimen): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroids only for 3 days
Trial: 18194120
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (steroid maintenance): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroid maintenance
Trial: 12133094
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTF) 2.5 ml (15‐20 microg.kg(‐1))
Trial: 12133094
Drug: Midazolam syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup (0.5 mg.kg(‐1))
Trial: 2181941
Drug: Protocol I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol I (5-FU 270-300 mg/m2 iv from day 1 to day 5 and ADM 25 mg/m2 iv on day 5)
Trial: 2181941
Drug: Protocol II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol II (5-FU, ADM plus CDDP 70 mg/m2 iv on day 1)
Trial: 31389672
Drug: Placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lotion for 8 weeks
Trial: 9031450
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 150 anti‐Xa units per kg body weight, administered subcutaneously every 12 h for 7 days, initiated prior to streptokinase (SK)
Trial: 9031450
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 100 anti‐Xa units per kg body weight, administered subcutaneously after dose reduction
Trial: 9031450
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 12,500 i.u. subcutaneously every 12 h for 7 days, initiated 4 h after start of SK infusion
Trial: 2104626
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (50 mg/week)
Trial: 2104626
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (100 mg/week)
Trial: 8132379
Drug: Control (sesame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sesame oil, 1 ml/week)
Trial: 2948735
Drug: t‐PA (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA (1.25 mg/kg iv over 3 hrs)
Trial: 19699531
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg injection 1 week before surgery
Trial: 16461054
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid (1.8 g ecosapentaenoic acid and 1.2 g docosahexaenoic acid)
Trial: 15266193
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (mean serum level 0.99 mEq/L)
Trial: 2610663
Drug: Alcohol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.85 g/kg)
Trial: 31688306
Drug: Herbal preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal preparation (myrrh, chamomile flowers, coffee charcoal)
Trial: 21732807
Drug: Aquatic exercise
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic exercise programme (14 weeks, 40 minutes per session, twice per week)
Trial: 14983492
Drug: Screening for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening for prostate carcinoma with systematic sextant needle biopsy for men with elevated PSA levels and/or positive findings on digital rectal examination or transrectal ultrasound.
Trial: 14983492
Drug: Curative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative treatment offered to patients diagnosed with PAC.
Trial: 9203228
Drug: Idazoxan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (100 micrograms/mg)
Trial: 9203228
Drug: Idazoxan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (200 micrograms/mg)
Trial: 7951859
Drug: Conservative medical
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative medical treatment without EIS
Trial: 7370145
Drug: Meptazinol 75
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 75 mg
Trial: 3277876
Drug: Self-administered intramuscular
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intramuscular analgesia
Trial: 21443301
Drug: Naltrexone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone with nicotine patch
Trial: 14629244
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injections (25 units into each corrugator supercilii muscle, total 50 units)
Trial: 20736816
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injections
Trial: 8665991
Drug: FER 5
RxNorm normalized name: Sur-Fit Wafer 57mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FER 5 mg 9 mm tablets
Trial: 8665991
Drug: FER 5
RxNorm normalized name: Sur-Fit Wafer 57mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FER 5 mg 11 mm tablets
Trial: 351351
Drug: Influenza subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza subunit vaccine
Trial: 12222085
Drug: Various psychopharmacologic
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various psychopharmacologic treatments (specific agents not mentioned)
Trial: 12222085
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies (specific agents not mentioned)
Trial: 12222085
Drug: Novel agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel agents (specific agents not mentioned)
Trial: 15590252
Drug: Remifentanil 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.02 mg
Trial: 20306569
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg kg(‐1) midazolam orally (group M)
Trial: 20306569
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg kg(‐1) midazolam orally with parental presence (group MP)
Trial: 15813848
Drug: Epoetin-β 150
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-β 150 IU/kg three times weekly for 16 weeks
Trial: 11034875
Drug: Stopping valproate
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stopping valproate administration
Trial: 8674327
Drug: Norepinephrine (pressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (pressor doses)
Trial: 18642046
Drug: Stapled transanal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stapled transanal rectal resection
Trial: 21762279
Drug: No neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neoadjuvant therapy and no enteral feeding products before surgery (Group 3, n=13)
Trial: 20472263
Drug: Silodosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (4 mg twice daily)
Trial: 7774212
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (DO2 > or = 600 mL/min/m2)
Trial: 9635648
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (DO2 450 to 550 mL/min/m2)
Trial: 28384627
Drug: Simultaneous group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous group (27 patients) received oral and intratympanic steroid injections for 2 weeks.
Trial: 28384627
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (23 patients) treated with oral steroids for 2 weeks and intratympanic steroids for the subsequent 2 weeks.
Trial: 31259
Drug: Nonselective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective beta-blockers
Trial: 15728228
Drug: Docetaxel/gemcitabine (DG):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/gemcitabine (DG): gemcitabine 1,000 mg/m(2) [days 1 and 8] plus docetaxel 100 mg/m(2) [day 8]
Trial: 15728228
Drug: Vinorelbine/cisplatin (VC):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine/cisplatin (VC): vinorelbine 30 mg/m(2) [days 1 and 8] plus cisplatin 80 mg/m(2) [day 8]
Trial: 8821071
Drug: Nootropic drugs
RxNorm normalized name: Other psychostimulants and nootropics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nootropic drugs
Trial: 8821071
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (nootropics)
Trial: 8821071
Drug: High L-dopa
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High L-dopa dosage
Trial: 8821071
Drug: Nootropic drugs
RxNorm normalized name: Other psychostimulants and nootropics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nootropic drugs (responders)
Trial: 8821071
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (non-responders)
Trial: 8821071
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (responders)
Trial: 8821071
Drug: Nootropic drugs
RxNorm normalized name: Other psychostimulants and nootropics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nootropic drugs (non-responders)
Trial: 2166455
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of inhaled terbutaline (LDT), 500 micrograms four times a day
Trial: 2166455
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of inhaled terbutaline (HDT), 2,000 micrograms four times a day
Trial: 7219673
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (DA) infusion (5 microgram/kg/min for 120 min)
Trial: 7219673
Drug: L-dopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (500 mg p.o.)
Trial: 7219673
Drug: L-dopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (100 mg p.o.) plus carbidopa (35 mg p.o.) after pretreatment with carbidopa (50 mg p.o. every 6 h for 1 day)
Trial: 7219673
Drug: Nomifensine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (200 mg p.o.)
Trial: 17599307
Drug: G-CSF (granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (granulocyte colony-stimulating factor), 263 mu g per day administered intravenously
Trial: 17599307
Drug: G-CSF (granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (granulocyte colony-stimulating factor)
Trial: 3051432
Drug: Weekly seminars
RxNorm normalized name: Semintra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly seminars with a cardiologist
Trial: 596499
Drug: Physicians (pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians (pill users)
Trial: 596499
Drug: Nurses (pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses (pill users)